CD34+CD38- leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agents.

COI Statement

Competing interests: LG holds membership on an entity’s board of directors or advisory committees for Miltenyi Biomedicine. AAvdL has received honoraria from Amgen, Novartis, Celgene/BMS, and Takeda and has received research funding from Alexion. DCdL participates in the sponsored speaker’s bureau of Servier, Roche and AbbVie; is part of the scientific advisory board of Takeda and Servier. GJO serves as a consultant for Novartis, Pfizer Inc, Celgene, Janssen, AGIOS, Amgen, Gilead, Astellas, Roche, Jazz Pharmaceuticals, and Merus; has received honoraria from Novartis, Celgene, AGIOS, Gilead, and Astellas; received research funding from Novartis; and holds membership on an entity’s board of directors for Roche. JC receives royalties from Navigate and BD Biosciences; participated in the sponsored speaker’s bureau of Astellas; and has received research funding from Takeda, DC-one, Genentech, Janssen, Novartis, and Merus. The remaining authors declare no competing financial interests. Ethics approval and consent to participate: Patients signed informed consent and the study was conducted according to the declaration of Helsinki. The study was approved by the medical ethics committee of the University Medical Center Groningen (number: 2015.550).

References:

• Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77.
• Jahn E, Saadati M, Fenaux P, Gobbi M, Roboz GJ, Bullinger L, et al. Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients. Leukemia. 2023;37:2187–96.
• Döhner H, DiNardo CD, Appelbaum F, Craddock C, Dombret H, Ebert BL et al. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood. 2024;144:blood.2024025409.
• Short NJ, Zhou S, Fu C, Berry DA, Walter RB, Freeman SD, et al. Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis. JAMA Oncol. 2020;6:1890–9.
• Huls G, Chitu DA, Pabst T, Klein SK, Stussi G, Griskevicius L, et al. Ibrutinib added to 10-day decitabine for older patients with AML and higher-risk MDS. Blood Adv. 2020;4:4267–77.